Apalutamide

Drug Profile

Apalutamide

Alternative Names: ARN-509; JNJ-56021927; JNJ-927

Latest Information Update: 06 Jun 2017

Price : $50

At a glance

  • Originator University of California System
  • Developer Case Comprehensive Cancer Center; Institut Paoli-Calmettes; Janssen Research & Development
  • Class Antiandrogens; Antihormones; Antineoplastics; Aza compounds; Benzamides; Pyridines; Small molecules; Spiro compounds; Sulfhydryl compounds; Thiohydantoins
  • Mechanism of Action Androgen receptor antagonists; Hormone inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Prostate cancer

Most Recent Events

  • 06 Jun 2017 University of Athens plans a phase II trial for Prostate cancer (Metastatic disease, Late-stage disease) (NCT03173859)
  • 17 May 2017 Johnson & Johnson Pharmaceuticals announces intention to submit regulatory filings for apalutamide in pre-metastatic Prostate cancer in between 2017 and 2021
  • 09 May 2017 Dana-Farber Cancer Institute and Janssen plan a phase II trial for Prostate cancer (Combination therapy) in USA (NCT03141671)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top